Abstract

A cancer treatment apparatus for applying a magnetic field to a living body is disclosed. The cancer treatment apparatus includes a magnetic field generator configured to generate a magnetic field; a power supply unit configured to supply a drive current to the magnetic field generator; and a controller configured to control the drive current supplied from the power supply unit, based on information on a cross section of a portion of a living body to which the magnetic field generated by the magnetic field generator is applied.

IPC Classes  ?

• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

Disclosed are a means which enables simple and rapid detection of the presence or absence, and of the degree, of HR activity in an individual, and a means which is useful for detection and treatment of homologous recombination-restored cancer for which no treatment means is available at present. The nucleic acid construct of the present invention is a nucleic acid construct comprising a set of a first nucleic acid molecule and a second nucleic acid molecule, the first nucleic acid molecule comprising: a promoter region; and a mutant gene sequence operably linked downstream thereof, the mutant gene sequence being constituted by a gene sequence encoding a protein and a cleavage site arranged inside thereof; the second nucleic acid molecule comprising a complementation region capable of replacing, by homologous recombination, a partial region comprising the cleavage site in the mutant gene sequence, the complementation region being constituted by a first homologous region and a second homologous region. The construct is useful as a measurement reagent or kit for homologous recombination activity, a diagnostic agent for homologous recombination-deficient cancer, a therapeutic agent for homologous recombination-restored cancer, or the like.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

[Problem] To provide a simpler testing method for a NAFLD or an assisting method for the diagnosis of a NAFLD, which is excellent in sensitivity and specificity. [Solution] Provided is a testing method for a nonalcoholic fatty liver disease (NAFLD), the method including a step for detecting or quantifying L-methionine in a biological sample derived from a subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

[Problem] To provide a simpler testing method for a NAFLD or an assisting method for the diagnosis of a NAFLD, which is excellent in sensitivity and specificity. [Solution] Provided is a testing method for a nonalcoholic fatty liver disease (NAFLD), the method including a step for detecting or quantifying D-histidine in a biological sample derived from a subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to construction of three-dimensional organs from pluripotent stem cells. The present disclosure also relates to a method of forming a cell condensate for self-organization.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12N 5/074 - Adult stem cells

Abstract

Provided is a forceps device (1) configured to easily change a state of a ratchet mechanism (19). The forceps device (1) includes an opening/closing drive unit (6) that opens an opening/closing portion (4) when positioned at an open position (O) and closes the opening/closing portion (4) when positioned at a closed position (C), and a ratchet mechanism (19) transitions between a restriction state in which the opening/closing drive unit (6) is restricted to move in the open position (O) direction and a restriction release state in which the move is not restricted. The ratchet mechanism (19) includes an operation portion (27) that projects rearward from a main body (3) of the forceps device (1) and is operated to cause the transition of the state of the ratchet mechanism (19).

IPC Classes  ?

• A61B 17/29 - Forceps for use in minimally invasive surgery
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

An alternating magnetic field having a frequency, at which a sufficient antitumor effect can be obtained, is enabled to be applied to a living body for a previously prescribed period of time while restricting an amount of heat generation from the living body. A cancer treatment apparatus includes a magnetic field generator configured to generate an alternating magnetic field to be applied to a living body, and a magnetic field controller configured to increase an intensity of the alternating magnetic field generated by the magnetic field generator stepwise until a first period of time elapses since application of the alternating magnetic field to the living body, and to set the intensity of the alternating magnetic field to a previously set maximum value from elapse of the first period of time until a timing to end the application of the alternating magnetic field.

IPC Classes  ?

• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

An alternating magnetic field having a frequency, at which a sufficient antitumor effect can be obtained, is enabled to be applied to a living body while restricting an amount of heat generation. A cancer treatment apparatus includes a magnetic field generator including a coil configured to generate an alternating magnetic field to be applied to a living body, and a cooler configured to cool a magnetic field application part of the living body in which a temperature rises in response to application of the alternating magnetic field.

IPC Classes  ?

• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

The present disclosure relates to an organ bud and a method of preparing an organ bud.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A01K 67/0271 - Chimeric vertebrates, e.g. comprising exogenous cells
• A61L 27/38 - Animal cells

Abstract

This heart failure estimation device acquires an image or video obtained by imaging the face of a patient. The heart failure estimation device extracts one or more feature parameters from the image or video. On the basis of the one or more feature parameters, the heart failure estimation device estimates the degree of heart failure of the patient.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• G06T 7/00 - Image analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention provides a means for reconstituting tissues and organs having mature functions.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The nucleic acid construct according to the present invention has such a structure that a protein can be expressed by the occurrence of at least two times of a recombinant reaction by single-strand annealing (SSA), is useful for the diagnosis and treatment of mismatch repair (MMR) deficient cancer, is applicable to the searching of a factor capable of regulating a reaction of MMR or SSA, an inhibitor or an activator for the reaction of MMR or SSA, and is also applicable to the prediction of whether of not a gene mutation identified in a cancer patient is a mutation that deteriorates an MMR activity. A conventional SSA construct that has been developed in the past by the present inventors has such a structure that a protein is expressed by the occurrence of one time of a SSA reaction. According to the construct of the present invention, the difference in the protein expression amount (activity) between the case where an MMR deficient is present and the case where an MMR deficient is absent occurs more greatly compared with that in the conventional SSA construct. Therefore, the construct of the present invention is expected to act on an MMR deficient cell more specifically and provide, for example, a treatment means having fewer adverse side effects.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

This culture device comprises a container body that houses a culture liquid, and a culture chip that forms a culture chamber inside the container body, wherein: the container body has a light-permeable and gas-permeable bottom wall; and the culture chip has a frame that is in contact with the top surface of the bottom wall, and a membrane member that is permeable to a liquid or a liquid-containing material and is fixed to the top surface of the frame to form the culture chamber together with the bottom wall and the frame.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/076 - Sperm cellsSpermatogonia

Abstract

A production method for an artificial organ according to the present invention involves performing a decellularization treatment on a mammalian organ or a portion thereof to obtain a decellularized organ or a portion thereof and performing a cellularization treatment that grafts cells onto the decellularized organ or portion thereof to obtain an organ onto which the cells have been grafted. The cellularization treatment involves injecting an organoid that includes cells of the relevant organ or cells that can differentiate into cells of the relevant organ into the decellularized organ or portion thereof and infusing the blood vessels of the decellularized organ or portion thereof with cells of the relevant organ or cells that can differentiate into cells of the relevale organ. An artificial organ according to the present invention is obtained by means of the production method for an artificial organ.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/078 - Cells from blood or from the immune system

Abstract

The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc.　A compound represented by formula (1) or a pharmaceutically acceptable salt thereof. (Here, in formula (1), R1, R2, R3, R4, X, Y, and Z are each as defined in the specification.)

IPC Classes  ?

• C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Provided is a culture chamber capable of preparing spheroids with a uniform size with high efficiency and having a micro-space structure which is designed to facilitate replacement of a medium and harvesting of cells. The culture chamber includes a plurality of recesses (10) each formed of a bottom portion (11) and an opening portion (12). The bottom portion (11) has one of a hemispherical shape and a truncated cone shape and the opening portion (12) is defined by a wall that surrounds an area from a boundary between the opening portion (12) and the bottom portion (11) to an end of each of the recesses (10), the wall having a taper angle in a range from 1 degree to 20 degrees. An equivalent diameter of the boundary is in a range from 50 μm to 2 mm and a depth from a bottom of the bottom portion (11) to the end of each of the recesses is in a range from 0.6 or more times to 3 or less times the equivalent diameter, and the wall defining the opening portion (12) forms a surface continuous to the bottom portion (11) and an inclination of the continuous surface changes at the boundary.

IPC Classes  ?

• C12M 1/24 - Apparatus for enzymology or microbiology tube or bottle type
• C12M 1/32 - Inoculator or sampler multiple field or continuous type

Abstract

An object of the present invention is to provide a biomarker that enables selection of an embryo having a high rate of implantation and pregnancy, that is, an embryo having high fertility, from embryos obtained through embryo culture after in vitro fertilization in infertility treatment, and a criterion therefor. Provided is a criterion that enables identification of an ovum suitable for implantation and pregnancy based on measurement of the concentration of soluble CD163 which is present in follicular fluid collected at the same time as an ovum in ovum pick up in infertility treatment, or which is present in serum immediately before the ovum pick up.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention provides a method for mass producing cell aggregates such as artificial organoids through an approach that differs entirely from previous methods. Specifically, provided is a method for producing cell aggregates that includes a step in which a mixture of mesenchymal stem cells, vascular endothelial cells, and organ cells are filled into microfibers, and the mixture is suspension cultured to form cell aggregates.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/407 - LiverHepatocytes
• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61L 27/38 - Animal cells
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

This information processing device acquires speech data that is time series data of the speech spoken by a user. The information processing device computes state information that represents a cardiac condition of a user, and outputs the computed condition information on the basis of the speech data.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention provides a marker gene capable of detecting the undifferentiated cells that remain or become included in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of LINC00678 and PRDM14 as an undifferentiation marker. A method of detecting undifferentiated cells; a method of using the gene as an undifferentiation marker; and a kit for detecting undifferentiated cells. A method of selecting an undifferentiated cell clone is also provided.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

A power supply apparatus includes a power supply configured to apply an alternating current to a magnetic field generation apparatus; and a controller configured to control the alternating current applied by the power supply. The controller controls the power supply to apply the alternating current having a waveform pattern including a plurality of current waveforms having different frequency spectrums from each other.

IPC Classes  ?

• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• H05B 6/06 - Control, e.g. of temperature, of power
• H05B 6/04 - Sources of current
• G03G 15/20 - Apparatus for electrographic processes using a charge pattern for fixing, e.g. by using heat

Abstract

[Object] To provide a cancer treatment device that monitors a magnetic field applied to an affected area or monitors a temperature of the affected area or around the affected area. [Means of Achieving the Object] A cancer treatment system includes a magnetic field generator configured to generate an alternating current magnetic field to be applied to a cancer affected area, a magnetic field measurer configured to measure a magnitude of the magnetic field generated by the magnetic field generator, wherein the cancer affected area is inserted into the magnetic field generated by the magnetic field generator to treat cancers.

IPC Classes  ?

• A61N 2/04 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets using variable fields, e.g. low frequency or pulsating fields

Abstract

An object of the present invention is to provide a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method which make it possible to simply detect SARS-CoV-2 with higher sensitivity. According to the present invention, there is provided a SARS-CoV-2 detection kit which is for specifically detecting a nucleocapsid protein contained in a biological specimen and contains at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), the SARS-CoV-2 detection kit including a first container that houses a silver-containing compound, and a second container that houses a reducing agent capable of reducing silver ions, in which the antibody includes at least one antibody that belongs to a subclass IgG2b.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/553 - Metal or metal coated

Abstract

The present invention addresses the problem of providing an evaluation method, etc., capable of providing reliable information that can be used as a reference for understanding an individual difference in the expression of the relative pharmacological action of a combination of an immune checkpoint inhibitor with an anticancer drug, which is a concomitant agent, compared to the pharmacological action of the immune checkpoint inhibitor alone. The present embodiment evaluates the relative pharmacological action of a combination of an immune checkpoint inhibitor with an anticancer drug, which is a concomitant agent, in a subject to be evaluated, compared to the pharmacological action of the immune checkpoint inhibitor alone, by using the concentration of at least one metabolite selected from among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA and XA in the blood of the subject to be evaluated.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention addresses the problem of providing a highly sensitive and highly specific means for detecting a protein constituting a nucleocapsid derived from SARS-CoV-2. The above problem has been solved by, for example, an antibody binding to a protein constituting the nucleocapsid derived from SARS-CoV-2 or a fragment thereof, or a combination thereof; a method for detecting, from a sample, a protein constituting the nucleocapsid derived from SARS-CoV-2 using said antibody or a fragment thereof, or a combination thereof; and a kit for detecting a protein constituting the nucleocapsid derived from SARS-CoV-2, the kit containing said antibody or a fragment thereof, or a combination thereof.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/531 - Production of immunochemical test materials
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus

Abstract

The present invention provides a sensitive and simple detection method, and a kit therefor, which detects residual undifferentiated human pluripotent stem cells in an intermediate product and/or a final product of a regenerative medical products, using an isothermal nucleic acid amplification method, and specifically, a LAMP method. A method for detecting presence or absence of undifferentiated cells in a non-undifferentiated cell population, wherein RNA derived from an undifferentiation marker gene exhibiting a significant difference in expression level between the undifferentiated cells and the non-undifferentiated cells in a sample containing a nucleic acid derived from the cell population of interest is detected by the isothermal nucleic acid amplification method. The kit for detecting presence or absence of undifferentiated cells in a non-undifferentiated cell population comprises a reagent with which RNA derived from an undifferentiation marker gene exhibiting a significant difference in expression level between the undifferentiated cells and the non-undifferentiated cells is detected by the isothermal nucleic acid amplification method.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

An object of the invention is to provide a method for detecting pancreatic cancer and a reagent that can be used for the method. The method is a method for detecting pancreatic cancer, characterized by comprising measuring the amount of TFPI2 in a body fluid collected from a subject. In addition, an antibody that specifically recognizes the TFPI2 processing polypeptide and intact TFPI2 is included in the reagent for detecting pancreatic cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided is a forceps device (1) that enables easy switching between states of a ratchet mechanism (19). The forceps device (1) comprises: an opening/closing drive part (6) that opens an opening/closing part (4) when positioned in an open position (O) and closes the opening/closing part (4) when positioned in a closed position (C); and a ratchet mechanism (19) that transitions between a restricted state in which movement of the opening/closing drive part (6) toward the open position (O) is restricted and an unrestricted state in which movement is not restricted. The ratchet mechanism (19) comprises an operation part (27) that protrudes rearward from a main body (3) of the forceps device (1) and is operated so as to transition the states of the ratchet mechanism (19).

IPC Classes  ?

• A61B 17/29 - Forceps for use in minimally invasive surgery

Abstract

Disclosed are a means which enables simple and rapid detection of the presence or absence, and of the degree, of homologous recombination activity in an individual, and a means which is useful for detection and treatment of homologous recombination-restored cancer for which no treatment means is available at present. The nucleic acid construct of the present invention comprises: (1) a promoter region; (2) a mutant gene sequence containing a cleavage site in a gene sequence encoding a protein; and (3) a base sequence composed of a first homologous region and a second homologous region, the base sequence being capable of replacing, by homologous recombination, a partial region in the mutant gene sequence of (2), the partial region containing the cleavage site. The nucleic acid construct of the present invention can be used as a measurement reagent or kit for homologous recombination activity, a diagnostic agent for homologous recombination-deficient cancer, a therapeutic agent for homologous recombination-restored cancer, or the like.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A cell evaluation method includes acquiring a first evaluation index and a first index calculated using the first evaluation index with respect to comparative target cells in a culture process including a cell differentiation-inducing process in which cell differentiation is induced, calculating a second index on the basis of the first evaluation index with respect to evaluation target cells different from the comparative target cells, and evaluating differentiation of the evaluation target cells by comparing the first index with the second index.

IPC Classes  ?

• G06T 7/00 - Image analysis
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

Disclosed is means which enables simple and rapid detection of the presence or absence of mismatch repair activity, and which is useful for diagnosis and treatment of mismatch repair-deficient cancers. In an integrated-type nucleic acid construct provided by the present invention, [promoter region], [5′-side region+first homologous region], and [second homologous region+3′-side region] are placed in the same nucleic acid molecule. In a divided-type nucleic acid construct, [promoter region], [5′-side region+first homologous region], and [second homologous region+3′-side region] are placed in two different nucleic acid molecules. The nucleic acid construct of the present invention can be used as a therapeutic agent for mismatch repair-deficient cancer, as a diagnostic agent for mismatch repair-deficient cancer, or as a companion diagnostic agent for predicting an effect of an anticancer drug for mismatch repair-deficient cancer, containing the nucleic acid construct.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• C07K 14/54 - Interleukins [IL]
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

An object of the present invention is to provide a method for detecting malignant ovarian tumor as distinguished from benign ovarian tumor, and a reagent that can be used for the method. Provided are a method for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor, characterized by measuring the amount of TFPI2 in a sample from a patient, and a reagent for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor contains an antibody that specifically recognizes TFPI2 processing polypeptide and intact TFPI2.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Developed is a method for creating cartilage tissue to solve the following problems. 1. Cartilage differentiation is not hindered by forming. 2. The cartilage can be formed into an intended shape without using a scaffold.　A method for producing artificial cartilage tissue comprises: forming a spheroid containing cartilage precursor cells into a desired shape while seeding the spheroid onto a support; culturing the spheroid while supplying a culture medium from the front side and the rear side of the surface onto which the spheroid has been seeded, and fusing the spheroids with each other; and maturing the fused spheroid into cartilage tissue in vitro.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells

Abstract

Disclosed are a means that enables simple, rapid detection of the existence and degree of HR activity in an individual and a means useful in the detection and treatment of homologous recombination repair cancers. The nucleic acid construct of the present invention includes a set of a first nucleic acid molecule and a second nucleic acid molecule. The first nucleic acid molecule includes a promoter region and, operably linked downstream thereof, a mutant gene sequence having a cleavage site in the interior of a gene sequence that encodes a protein, and the second nucleic acid molecule includes a complementary region constituting a first homologous region and a second homologous region capable of substituting by homologous recombination the partial region including the cleavage site in the mutant gene sequence. The construct is useful as a reagent or kit for measuring homologous recombination activity, as a diagnostic agent for homologous recombination deletion cancers, as a therapeutic agent for homologous recombination repair cancers, etc.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The disclosure provides a method for producing hepatocytes or hepatic progenitor cells; a method for suppressing hepatocyte aging using a drug causing histone hyperacetylation; a hepatocyte anti-aging agent; a method for increasing hepatocyte plasticity; and a drug for increasing hepatocyte plasticity.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A cancer treatment apparatus including a magnetic field generator that generates a magnetic field of 100 kHz to 300 kHz to be applied to affected tissues.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

The present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis. The first nucleic acid comprises a first common sequence tract, a variable sequence tract and a second common sequence tract and the second nucleic acid comprises a first common sequence tract, optionally an variable sequence tract and a second common sequence tract. The first and the second nucleic acid sequence is contacted with a probe sequence that is reverse complementary to the first and second common sequence tract under conditions allowing the hybridization of the probe sequence to the first and second nucleic acid sequence, thereby forming a first probe hybrid and a second probe hybrid. Subsequently, the first and second probe hybrids are submitted to electrophoresis to detect the electrophoretic mobility of the first and second probe hybrid.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• G01N 27/447 - Systems using electrophoresis

Abstract

A method for screening for a therapeutic drug for a disease involving excessive activation of a complement, using a s cytotoxicity marker associated with the complement as an index, including (1a) a step of adding a complement to a cell produced from a stem cell to cause the cell to form a cytotoxicity marker associated with the complement, and (2a) a step of adding a therapeutic drug candidate, and selecting a substance that decreases the amount of the cytotoxicity marker is provided by the present invention.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The purpose of the present invention is to provide: a biomarker by which embryos having a high implantation/pregnancy probability, i.e., having high fertility can be selected from among embryos obtained by in vitro fertilization and then embryo culturing in infertility treatment; and a determination criterion thereof. The present invention provides a criterion with which an egg suitable for implantation/pregnancy can be determined, by measuring the concentration of soluble CD163 present in a follicular fluid to be collected simultaneously with the egg at the time of egg collection in infertility treatment or in a serum immediately before the egg collection.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/12 - Genes encoding animal proteins
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The purpose of the present invention is to provide: a biomarker by which embryos having a high implantation/pregnancy probability, i.e., having high fertility can be selected from among embryos obtained by in vitro fertilization and then embryo culturing in infertility treatment; and a determination criterion thereof. The present invention provides a criterion with which an egg suitable for implantation/pregnancy can be determined, by measuring the concentration of soluble CD163 present in a follicular fluid to be collected simultaneously with the egg at the time of egg collection in infertility treatment or in a serum immediately before the egg collection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/12 - Genes encoding animal proteins
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Provided are: a method for producing a non-human model animal with a mental disorder or neurological disorder that is attributed to an increase or decrease in the expression of an AMPA receptor gene or an increase or decrease in the expression or function of an AMPA receptor in a predetermined region in the brain; a non-human model animal with the mental disorder or neurological disorder; and a screening method for discovering a prophylactic or therapeutic agent for the mental disorder or neurological disorder, using the non-human model animal.　This method is for producing a non-human model animal with a mental disorder or neurological disorder that is attributed to an increase or decrease in the expression of an AMPA receptor gene or an increase or decrease in the expression or function of an AMPA receptor in a predetermined region in the brain. The method comprises: a step for decreasing or increasing at least one selected from the group consisting of the expression of the AMPA receptor gene or the AMPA receptor, and the function of the AMPA receptor, in the predetermined region of the non-human animal, compared to a wild type, or a step for inhibiting or activating a nervous pathway connecting the predetermined region with another region.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/12 - Genes encoding animal proteins

Abstract

The present invention provides means for producing an organoid close to an organ in a living body and capable of secretion of a plasma protein and immune response. A matrix composition of the present invention provided as such means includes: (1) a first matrix containing one or more cells selected from the group consisting of vascular cells, nerve cells, and blood cells; and (2) a second matrix containing to cells constituting an organ and/or an organoid, in which the first matrix envelops the second matrix, and the first matrix has at least one opening.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

Provided is a coating-fixing agent for transplanting a cell or a tissue onto the surface of an organ, intestinal membrane, peritoneal membrane, etc. Provided are: a formulation for coating and fixing a graft, the formulation comprising alginate; a formulation kit for coating and fixing a graft, comprising a formulation containing alginate and a divalent or higher valent metal salt in combination; and a method for transplanting a graft, comprising: transplanting the graft to a transplant site of a human or a non-human animal, and coating the graft with alginate.

IPC Classes  ?

• A61L 24/08 - Polysaccharides
• C09D 105/04 - Alginic acidDerivatives thereof

Abstract

The present invention provides a method of constituting a tissue construct in vitro using a tissue without depending on scaffold materials. A method of integrating a biological tissue with a vascular system in vitro, comprising coculturing a biological tissue with vascular cells and mesenchymal cells. A biological tissue which has been integrated with a vascular system by the above-described method. A method of preparing a tissue or an organ, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of regeneration or function recovery of a tissue or an organ, comprising transplanting the biological tissue described above into a human or a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of preparing a non-human chimeric animal, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or organ in which vascular networks have been constructed. A method of evaluating a drug, comprising using at least one member selected from the group consisting of the biological tissue described above, the tissue or organ prepared by the method described above, and the non-human chimeric animal prepared by the method described above. A composition for regenerative medicine, comprising a biological tissue which has been integrated with a vascular system by the method described above.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07D 499/21 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
• A61L 27/38 - Animal cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present invention addresses the problem of providing a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method that enable the detection of SARS-CoV-2 in a simple manner and with higher sensitivity. The present invention provides a SARS-CoV-2 detection kit for specifically detecting a nucleocapsid protein (NP) contained in a biological sample, the SARS-CoV-2 detection kit comprising at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), wherein the antibody includes at least one antibody of which the subclass is IgG2b, and the kit includes a first container that receives a silver-containing compound, and a second container that receives a reducing agent that can reduce silver ions.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention provides a means for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells. The nutrition composition according to the present invention is a nutrition composition for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells, the nutrition composition containing at least one essential amino acid selected from the group consisting of isoleucine, leucine, methionine, lysine, phenylalanine, tryptophan, threonine and histidine except valine, and optionally containing a non-essential amino acid(s).

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/175 - Amino acids

Abstract

A game device (10) is provided with: an input unit (11A) that receives input of a physical amount which reflects at least one of a respiratory function, a deglutition function, and a vocalization function by a user who plays a game and which has a parameter with a state thereof made variable; and an adjustment unit (11B) for adjusting the parameter to be more advantageous in the development of the game as the degree in which, the state of the physical amount inputted by the input unit (11A) becomes effective as training for at least one of the respiratory function, the deglutition function, and the vocalization function of the user, become higher.

IPC Classes  ?

• A63F 13/215 - Input arrangements for video game devices characterised by their sensors, purposes or types comprising means for detecting acoustic signals, e.g. using a microphone
• A63F 13/46 - Computing the game score
• A63F 13/53 - Controlling the output signals based on the game progress involving additional visual information provided to the game scene, e.g. by overlay to simulate a head-up display [HUD] or displaying a laser sight in a shooting game
• A63F 13/69 - Generating or modifying game content before or while executing the game program, e.g. authoring tools specially adapted for game development or game-integrated level editor by enabling or updating specific game elements, e.g. unlocking hidden features, items, levels or versions

Abstract

Provided is a schizophrenia biomarker. A schizophrenia examination method including measuring the expression level of non-phosphorylated collapsin response mediator protein 2 (CRMP2) and/or phosphorylated CRMP2 in a sample derived from a subject.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides a composition suitable as a composition for treating blood coagulation and/or complement disorders (raw materials for producing therapeutic agents for these diseases) and a method for effectively producing the composition. A method for producing a composition for treating blood coagulation and/or complement disorders according to the present invention includes the following steps of: (1) embedding an organoid formed from vascular endothelial cells or vascular endothelial cells and hepatocytes, in an extracellular matrix; (2) culturing the extracellular matrix; and (3) collecting a culture supernatant from the culture obtained in the step (2).

IPC Classes  ?

• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents

Abstract

Provided is a means for rapidly analyzing whether an interstitial pneumonia patient, who exhibits a respiratory distress symptom and is suspected to suffer from an acute exacerbation, suffers from an acute exacerbation or suffers from an acute respiratory exacerbation caused by a pathosis that is not an acute exacerbation. Provided is a method comprising: a step for obtaining the measured value of the concentration of heme oxygenase-1 in a blood specimen collected from an interstitial pneumonia patient exhibiting a respiratory distress symptom; and a step for determining, on the basis of the measured value, whether the symptom of the patient is caused by an acute exacerbation or caused by a pathosis that is not an acute exacerbation. Moreover, provided are: a kit for performing said method; and a patient sorting method and a treatment policy determination method which are based on said method.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The purpose of the present invention is to provide a food composition, a pharmaceutical composition, a quasi drug composition, a cosmetic composition and a sundry article, each being for preventing or treating COVID-19. A food composition, a pharmaceutical composition, a quasi drug composition, a cosmetic composition and a sundry article, each being for preventing or treating COVID-19 and comprising at least one member selected from among a cat's claw extract, a ginger extract, pteropodine and a pharmaceutically acceptable salt thereof, isopteropodine and a pharmaceutically acceptable salt thereof, 6-gingerol and a pharmaceutically acceptable ether thereof and 6-shogaol and a pharmaceutically acceptable ether thereof.

IPC Classes  ?

• A61K 36/74 - Rubiaceae (Madder family)
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 31/12 - Ketones
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61P 31/14 - Antivirals for RNA viruses
• A61Q 1/00 - Make-up preparationsBody powdersPreparations for removing make-up
• A61Q 5/02 - Preparations for cleaning the hair
• A61Q 5/06 - Preparations for styling the hair, e.g. by temporary shaping or colouring
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention provides a prophylactic and/or therapeutic agent for diseases accompanied by fibrosis. A pharmaceutical composition for preventing and/or treating a disease accompanied by fibrosis in an organ and/or a tissue, which comprises a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and hepatocytes, optionally). An agent capable of inhibiting organ and/or tissue fibrosis, which comprises both mesenchymal cells and vascular cells or a cell condensate thereof. By transplanting into a subject a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and optionally, hepatocytes), expression levels of fibrolysis enzymes (fibrolytic factors) such as MMP1 or MMP13 are elevated, which eventually enables inhibition of fibrosis in an organ and/or a tissue, as well as prevention and/or treatment of a disease accompanied by fibrosis in an organ and/or a tissue.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61K 35/407 - LiverHepatocytes
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/06 - Tripeptides
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A bilirubin concentration measurement system including: a sensor device attachable to a subject; and a terminal device capable of wirelessly communicating with the sensor device. The sensor device includes: a light emitting diode that emits blue light; a light emitting diode that emits green light; a light detection diode that detects reflected light that is the blue light having been incident on skin of the subject and reflected, and detects reflected light that is the green light having been incident on the skin of the subject and reflected; and a communication unit that wirelessly transmits information about intensities of the reflected light detected by the photodiode. The terminal device includes: a communication unit that receives the information about the intensities of the reflected light transmitted from the sensor device; and a computing unit that calculates a bilirubin concentration using the information about the intensities of the reflected light.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/13 - Immunoglobulins
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention addresses the problem of providing a method for detecting pancreatic cancers and a reagent usable in the method. The method for detecting pancreatic cancers is characterized by measuring the amount of TFPI2 in body fluid sampled from a subject. Furthermore, an antibody that specifically recognizes TFPI2 processing polypeptide and intact TFPI2 is included in the reagent for detecting pancreatic cancers.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 15/12 - Genes encoding animal proteins
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode

Abstract

The present invention addresses the problem of providing a means for accurately, easily and quickly detecting an anti-SARS-CoV-2-antibody. A solution to this problem is achieved by providing a SARS-CoV-2-derived nucleocapsid fragment, a method and a kit for detecting an anti-SARS-CoV-2-antibody from human-derived blood, plasma and/or serum with the use of the fragment, etc.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/535 - Production of labelled immunochemicals with enzyme label
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The purpose of the present invention is to provide a mouse model for pancreatic cancer similar to human pancreatic cancer. Specifically, the present invention pertains to a human pancreatic cancer mouse model which carries a pancreatic cancer organoid containing a human pancreatic cancer cell line S2-130.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/09 - Tumour cells
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

The present invention addresses the problem of providing a method for detecting malignant ovarian tumors distinctly from benign ovarian tumors and a reagent that can be used in the method. This method for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors is characterized in that the amount of TFPI2 in a sample originating from a patient is measured. In addition, an antibody that specifically recognizes TFPI2 processing polypeptide and intact TPFI2 is included in a reagent for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention addresses the problem of providing a method for detecting malignant ovarian tumors distinctly from benign ovarian tumors and a reagent that can be used in the method. This method for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors is characterized in that the amount of TFPI2 in a sample originating from a patient is measured. In addition, an antibody that specifically recognizes TFPI2 processing polypeptide and intact TPFI2 is included in a reagent for detecting malignant ovarian tumors (excluding high-grade serous carcinoma) distinctly from benign ovarian tumors.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides a marker gene capable of detecting the undifferentiated cells that remain or become included in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of ESRG, VSNL1, THY1, SFRP2, SPP1, USP44 and CNMD as an undifferentiation marker. A method of detecting undifferentiated cells; a method of using the gene as an undifferentiation marker; and a kit for detecting undifferentiated cells. A method of selecting an undifferentiated cell clone is also provided.

IPC Classes  ?

• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed are a means that enables the rapid and convenient detection of the presence/absence and extent of homologous recombination activity in an individual, and a means that is not a current treatment means and is useful for the detection and treatment of homologous recombination repair cancers. A nucleic acid construct according to the present invention comprises (1) a promoter region, (2) a mutant gene sequence that has a cleavage site in the interior of a protein-encoding gene sequence, and (3) a base sequence that is a partial region in the mutant gene sequence of (2), is capable of replacing, by homologous recombination, a partial region that contains the cleavage site, and is constituted of a first homologous region and a second homologous region. This nucleic acid construct can be used, for example, as a reagent or kit for measuring homologous recombination activity, as a diagnostic agent for homologous recombination deletion cancers, and as a therapeutic agent for homologous recombination repair cancers.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/869 - Herpesviral vectors
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed is a means that enables simple and quick detection of the presence or absence of a mismatch repair activity and that is useful in diagnosing or treating mismatch repair deficient cancers. In an integrated type nucleic acid construct provided by the present invention, [promoter region], [5' terminal region + first homologous region] and [second homologous region + 3' terminal region] are disposed on a single nucleic acid molecule. In a split type nucleic acid construct, [promoter region] and [5' terminal region + first homologous region] are disposed on a nucleic acid molecule and [second homologous region + 3' terminal region] are disposed on another nucleic acid molecule that is different from the former nucleic acid molecule. The nucleic acid construct of the present invention can be used as a therapeutic agent for mismatch repair deficient cancers, a diagnostic agent for mismatch repair deficient cancers, a companion diagnostic agent for predicting the effect of an anticancer agent on mismatch repair deficient cancers, etc., each agent comprising the nucleic acid construct.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/475 - Growth factorsGrowth regulators
• C07K 14/525 - Tumour necrosis factor [TNF]
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Provided is a maturation prediction system improved in terms of ease of use, versatility, and prediction accuracy.　This maturation prediction system for plants is characterized in that the system generates a first model for which weather information is input and a predicted intermediate state of a plant of interest is output and a second model for which information about the intermediate state is input and a prediction of maturation of the plant of interest is output, and in that weather information for a predicted maturation time is input to the first model and the predicted intermediate state of the plant of interest at the predicted maturation time output from the first model is input to the second model, thereby outputting a prediction of maturation of the plant of interest at the predicted maturation time.

IPC Classes  ?

• A01G 7/00 - Botany in general
• G06Q 50/02 - AgricultureFishingForestryMining

Abstract

The present invention addresses the problem of providing a biomarker that makes it possible to diagnose colon cancer.　The present invention relates to a biomarker that is for assisting in the diagnosis of colon cancer and that contains a sugar chain selected from among the following substances (1)-(4): (1) at least one sugar chain that is present in alpha 1-antitrypsin and represented by formula 1 or 2; (2) a sugar chain that is present in leucine-rich alpha-2 glycoprotein and represented by formula 1; (3) at least one sugar chain that is present in alpha 1-antichymotrypsin and represented by formula 1 or 2; and (4) a sugar chain that is present in complement component 9 and represented by formula 1.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/81 - Protease inhibitors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/15 - Protease inhibitors, e.g. antithrombin, antitrypsin, hirudin
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Faecalibacterium bacterium or a processed product thereof.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Provided is a marker gene capable of detecting the persistence/admixture of undifferentiated cells in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of LINC00678 and PRDM14 as an undifferentiation marker. Also provided are a method for detecting undifferentiated cells, a method of use as an undifferentiation marker, and an undifferentiated cell detection kit, and a method for selecting an undifferentiated cell line.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/09 - Tumour cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6841 - In situ hybridisation
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6862 - Ligase chain reaction [LCR]
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6872 - Methods for sequencing involving mass spectrometry
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Provided is a sensitive and simple detection method, and a kit therefor, which detects undifferentiated human pluripotent stem cells which are mixed into an intermediate product of a regenerative medicine product and/or a final product thereof by using a nucleic acid isothermal amplification method, and specifically, the LAMP method. A method for detecting whether or not undifferentiated cells are present in a non-undifferentiated cell population, wherein RNA derived from an undifferentiated marker gene for which there is a significant difference in expression between an undifferentiated cell and a non-undifferentiated cell is detected using a nucleic acid isothermal amplification method in a specimen containing a nucleic acid derived from the cell population to be tested. A kit for testing whether or not undifferentiated cells are mixed in with a non-undifferentiated cell population, said kit containing a reagent capable of detecting RNA derived from an undifferentiated marker gene for which there is a significant difference in expression between an undifferentiated cell and a non-undifferentiated cell by using a nucleic acid isothermal amplification method.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

This cell evaluation method comprises: in a culture stage involving the induction of cell differentiation during a process for inducing the cell differentiation, acquiring a first evaluation index relative to cells to be compared and a first index calculated with the use of the first evaluation index; calculating a second index relative to cells to be evaluated, said cells to be evaluated being different from the cells to be compared, on the basis of the first evaluation index; and then comparing the first index with the second index to thereby evaluate the differentiation of the cells to be evaluated.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

The present invention provides a drug toxicity evaluation platform (evaluation method and kit therefor, etc.) that makes it possible to perform a detailed analysis of the likelihood that a drug will cause injury (DILI, etc.) to the liver or another organ. This method for evaluating drug toxicity includes a step for adding a drug to a co-culture of an organoid and blood cells, and a step for evaluating the toxicity of said drug to said organoid.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/078 - Cells from blood or from the immune system
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Provided are: a method for inducing hepatic progenitor cells which can overcome drawbacks in the prior art; and hepatic progenitor cells. Hepatocyte plasticity and senescence are controlled. A method for producing hepatocytes that includes dividing endodermal cells into hepatocytes in the presence of a member of the FGF family, HGF, and a member of IL6 family, and dexamethazone. Hepatocytes produced using the aforementioned method that can survive for 90 or more days while maintaining functionality as hepatocytes. A method for producing hepatic progenitor cells that includes culturing hepatocytes in the presence of a member of the FGF family. Alpha-fetoprotein (AFP)–negative hepatic progenitor cells produced using the aforementioned method that have proliferative ability and the ability to differentiate bidirectionally into hepatocytes and bile duct epithelial cells. A method for producing hepatocytes that includes inducing differentiation of the hepatic progenitor cells into hepatocytes. A method for producing bile duct cells that includes inducing differentiation of the hepatic progenitor cells into bile duct cells. A method for suppressing hepatocyte senescence using a drug which causes histone hyperacetylation. A hepatocyte senescence inhibitor that includes a drug that causes histone hyperacetylation as an active ingredient. A method for increasing hepatocyte plasticity using a drug that causes histone hyperacetylation. A drug that increases hepatocyte plasticity and includes a drug that causes histone hyperacetylation as an active ingredient. A method for producing a chimeric animal that includes transplanting into a non-human animal at least one cell selected from the group consisting of the hepatocytes, the hepatic progenitor cells, and the cells induced through differentiation from the hepatic progenitor cells. A composition for transplantation that includes at least one cell selected from the group consisting of the hepatocytes, the hepatic progenitor cells, and the cells induced by differentiation from the hepatic progenitor cells. A culture medium kit for inducing differentiation that includes: an agent containing FGF10, retinoic acid, and forskolin for use in a culture medium to be used to induce differentiation of the hepatic progenitor cells into bile duct cells; and a written explanation of the use of the agent in the culture medium to be used to induce differentiation. A medium containing FGF10, retinoic acid, and forskolin for inducing differentiation of the hepatic progenitor cells into bile duct cells. A liver regeneration promoter that includes a drug that causes histone hyperacetylation as an active ingredient.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 35/407 - LiverHepatocytes
• A61L 27/38 - Animal cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

An object of the present invention is to provide a method for detecting renal cancer, and a reagent that can be used for the method. Provided is a method for detecting renal cancer, which includes measuring the amount of TFPI2 in a sample derived from a patient. An antibody that specifically recognizes NT-TFPI2 and intact TFPI2 is included in a detection reagent for renal cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis. The first nucleic acid comprises a first common sequence tract, a variable sequence tract and a second common sequence tract and the second nucleic acid comprises a first common sequence tract, optionally an variable sequence tract and a second common sequence tract. The first and the second nucleic acid sequence is contacted with a probe sequence that is reverse complementary to the first and second common sequence tract under conditions allowing the hybridization of the probe sequence to the first and second nucleic acid sequence, thereby forming a first probe hybrid and a second probe hybrid. Subsequently, the first and second probe hybrids are submitted to electrophoresis to detect the electrophoretic mobility of the first and second probe hybrid.

IPC Classes  ?

• C12Q 1/6813 - Hybridisation assays

Abstract

The present invention provides a method of fusing cell masses. A method of fusing cell masses, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane.

IPC Classes  ?

• C12N 5/16 - Animal cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Disclosed is a novel means for accurate qualitative and quantitative analyses for each N-glycosylation site. The method of analyzing N-linked sugar chain(s) of glycoprotein according to the present invention comprises: treating a part of a glycopeptide-containing sample to be analyzed with endo-β-N-acetylglucosaminidases to cleave off sugar chains while leaving one GlcNAc of the chitobiose core on the Asn at the N-glycosylation site; subjecting the obtained sugar chain-cleaved sample to preliminary liquid chromatography/mass spectrometry; predicting the retention time of the glycopeptide of interest and the mass-to-charge ratio (m/z) of the precursor ion in main analysis based on the results of the preliminary liquid chromatography/mass spectrometry; and carrying out the main analysis. By this method, the binding sites and structures of N-linked sugar chains in a glycoprotein can be analyzed. By using the sugar chain-cleaved sample as an internal standard in the main analysis, quantitative analysis of sugar chains at each glycosylation site also becomes possible.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• G01N 30/72 - Mass spectrometers
• G01N 30/86 - Signal analysis
• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 30/02 - Column chromatography

Abstract

The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12N 5/074 - Adult stem cells

Abstract

A method for aggregating cell masses includes performing a cell mass aggregating step of rotating a rotating body containing a specific gravity adjustment solution and cell masses to aggregate the cell masses, the specific gravity adjustment solution having biocompatibility, the cell masses having a lower specific gravity than the specific gravity adjustment solution.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided is an illness aggravation estimation system that estimates aggravation of an illness in a patient with high precision. The illness aggravation estimation system acquires sickbed image data in which images of an imaging area including the sickbed of a patient are captured chronologically, analyzes the movements of the patient or of a body part of the patient captured in the acquired sickbed image data, uses the analyzed movements as a basis to perform scoring of at least one of a consciousness state and oxygen administration which are items included in indices for an early warning score, and estimates aggravation of an illness in the patient.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention provides a method for screening a therapeutic agent of a disease, in which over-activation of a complement is engaged, by taking, as an indicator, a cytotoxic marker associated with the complement, wherein the method includes: (1a) a process for adding the complement to a cell manufactured from a stem cell, and forming the cytotoxic marker associated with the complement; and (2a) a process for adding a therapeutic agent candidate material to select a material which lowers the amount of the cytotoxic marker.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/6851 - Quantitative amplification
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a means for producing an organoid capable of secretion of plasma proteins, immune response, etc., in a manner close to that of an organ in a living body. As such a means, this matrix composition includes: (1) a first matrix that includes one or more cells selected from the group comprising vascular cells, nerve cells, and blood cells; (2) a second matrix that includes cells constituting an organ, and/or an organoid, and here, the first matrix encapsulates the second matrix, and the first matrix has at least one opening.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Provided is a coating-securing agent for transplanting cells or a tissue onto the surface of an organ, a mesentery, a peritoneum, etc. Provided are: a formulation which is for coating-securing an implant, and contains alginate; a formulation kit for coating-securing an implant, in which an alginate-containing formulation and a di- or higher-polyvalent metallic salt are combined; and a method for transplanting an implant, the method comprising a step for transplanting an implant onto a transplantation site of a human or a non-human animal and coating the implant with alginate.

IPC Classes  ?

• A61L 31/02 - Inorganic materials
• A61L 31/04 - Macromolecular materials
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• C12N 11/04 - Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
• C12N 11/10 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
• A61L 27/20 - Polysaccharides

Abstract

An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/06 - Tripeptides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention provides a composition suitable for treating blood coagulation and/or complement disorders (a raw material for producing a therapeutic agent for such disorders) and an effective production method therefor. This method for producing a composition for treating blood coagulation and/or complement disorders comprises the following steps: (1) a step in which an organoid prepared from vascular endothelial cells or from vascular endothelial cells and liver cells is embedded in an extracellular matrix; (2) a step in which the extracellular matrix is cultivated; and (3) a step in which a culture supernatant is recovered from the culture cultivated in step (2).

IPC Classes  ?

• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 37/02 - Immunomodulators
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61K 38/37 - Factors VIII
• A61K 35/407 - LiverHepatocytes
• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells

Abstract

The present invention provides a system for artificially inducing and regulating “tissue interactions” among multiple tissues. A construct for transplantation into a living body, which comprises a structure and a cell mass linked to each other, the structure being an object having a three-dimensional structure and capable of mimicking or resembling a structure and/or a function of the living body.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Provided is a method for predicting, in the stage of undifferentiated cells, the possibility of contamination with undifferentiated cells after the differentiation of the cells. The differentiation resistance of undifferentiated cells is evaluated by measuring (i) and/or (ii). (i) Expression level and/or promoter activity of at least one gene selected from the group consisting of ZNF354C, C12orf56, ZNF578, DPP6 and MIR886. (ii) Methylation state of the promoter of at least one gene selected from the group consisting of ZNF354C, C12orf56, ZNF578, DPP6 and MIR886.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/095 - Stem cellsProgenitor cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6841 - In situ hybridisation
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided is a prophylactic and/or therapeutic agent for diseases accompanied by fibrosis. The present invention provides: a medicinal composition for preventing and/or treating diseases accompanied by organ and/or tissue fibrosis, the composition comprising a cell mixture and/or a cell aggregate that includes mesenchymal cells and endothelial cells (hepatocytes may be further included); and an inhibitor for inhibiting organ and/or tissue fibrosis, the inhibitor comprising both mesenchymal cells and endothelial cells or a cell aggregate thereof. A cell mixture and/or a cell aggregate that includes mesenchymal cells and endothelial cells (hepatocytes may be further included) is transplanted to a subject, so that an expression of fibrinolysins such as MMP1 and MMP13 (fibrinolytic system factors) increases and can inhibit organ and/or tissue fibrosis, thereby preventing and/or treating diseases accompanied by organ and/or tissue fibrosis.

IPC Classes  ?

• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 35/407 - LiverHepatocytes
• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61L 27/38 - Animal cells

Abstract

A bilirubin concentration measurement system (1) according to the present invention is provided with a sensor device (10) attachable to a test body, and a terminal device (20) capable of wirelessly communicating with the sensor device (10). The sensor device (10) is provided with: a light emitting element (12) which emits blue light; a light emitting element (13) which emits green light; an optical detection element (14) which detects reflected light due to the blue light incident on, and reflected by, a skin of the test body, and reflected light due to the green light incident on, and reflected by, the skin of the test body; and a communication unit (16) which wirelessly transmits information pertaining to the intensity of the reflected light detected by the optical detection element (14). The terminal device (20) is provided with a communication unit (21) which receives the information pertaining to the intensity of the reflected light transmitted from the sensor device (10), and a computing unit (22) which calculates a bilirubin concentration using the information pertaining to the intensity of the reflected light.

IPC Classes  ?

• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

The present invention provides a means for inhibiting formation and/or growth of non-objective cells derived from stem cells in a cell population including cells differentiated from the stem cells. A nutrition composition according to the present invention contains one or more essential amino acids selected from the group consisting of isoleucine, leucine, methionine, lysine, phenylalanine, tryptophan, threonine, and histidine, but excluding valine, optionally contains a nonessential amino acid, and inhibits formation and/or growth of non-objective cells derived from stem cells in a cell population including cells differentiated from the stem cells.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A23L 33/175 - Amino acids
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells

Abstract

Provided is a reproductive medicine support system which supports persons who are involved and work in reproductive medicine. Image analysis processing performed by an analysis means includes: determination processing for determining sperm imaged in video data; and analysis processing for analyzing the sperm determined in the determination processing. On a working screen, displayed are first additional displays (displays G11–G13) based on the analysis processing pertaining to sperm displayed in a display region on a main screen G1 among the sperm determined by the determination processing; and second additional displays (displays G22-G25) based on the analysis processing pertaining to all the sperm determined by the determination processing or sperm displayed in a display region of a sub-screen G2 among the sperm determined by the determination processing.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry

Abstract

The present invention addresses the problem of providing a pancreatic cancer determination marker having a high accuracy (correctness and precision). The present invention pertains to a pancreatic cancer determination marker, a pancreatic cancer determination method, a method for acquiring data for determining a pancreatic cancer, a pancreatic cancer determination kit, and the like.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose

Abstract

Provided is a marker gene capable of detecting the persistence/admixture of undifferentiated cells in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of ESRG, VSNL1, THY1, SFRP2, SPP1, USP44, and CNMD as an undifferentiation marker. A method for detecting undifferentiated cells, a method of use as an undifferentiation marker, and an undifferentiated cell detection kit. Also provided is a method for selecting an undifferentiated cell line.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6841 - In situ hybridisation
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

A power supply apparatus includes a power supply configured to apply an alternating current to a magnetic field generation apparatus; and a controller configured to control the alternating current applied by the power supply. The controller controls the power supply to apply the alternating current having a waveform pattern including a plurality of current waveforms having different frequency spectrums from each other.

IPC Classes  ?

• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• H05B 6/06 - Control, e.g. of temperature, of power
• H05B 6/04 - Sources of current
• G03G 15/20 - Apparatus for electrographic processes using a charge pattern for fixing, e.g. by using heat

Abstract

A cancer treatment apparatus including a magnetic field generator that generates a magnetic field of 100 kHz to 300 kHz to be applied to affected tissues.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

The purpose of the invention is to provide a method for identifying molecules involved in refractory cancers. Furthermore, the purpose of the invention is to provide a method for identifying drugs effective against refractory cancers. Additionally, the purpose of the invention is to provide a drug effective against recurrent cancers. Provided is a method for screening for molecules involved in refractory cancers, wherein the expression level of an EMT-associated molecule at pre- and post-administration of an anticancer agent is measured in stromal cells and/or cancer cells in tissue that reconstructs the cancer microenvironment, and an EMT-associated molecule presenting a higher expression level at post-administration of the anticancer agent than at pre-administration is scored as being involved in refractory cancers. Also provided is a method for screening for drugs effective against refractory cancers, wherein the expression level of an EMT-associated molecule at pre- and post-administration of an anticancer agent is measured in stromal cells and/or cancer cells in tissue that reconstructs the cancer microenvironment, and an EMT-associated molecule presenting a higher expression level at post-administration of the anticancer agent than at pre-administration is scored as being involved in refractory cancers, while a substance that can inhibit the function of this EMT-associated molecule is scored as a drug effective against refractory cancers. Further provided is a drug for treating and/or preventing tumor recurrence as a combination of an anticancer agent with an inhibitor targeted to the NOTCH3 signal.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided is a technique for accurately evaluating the prognosis of a cancer. This method comprises: measuring the expression level of an EMT-related molecule in cancer cells and stromal cells in a cancer tissue from a patient or a tissue reconstructing the cancer microenvironment including cancer cells from the patient; and predicting the prognosis of the patient on the basis of this level.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

Provided is a method for fusing cell masses. The cell mass fusion method comprises: disseminating cell masses on a surface to which cells can adhere; and culturing the cell masses while supplying a culture medium from the front side and the rear side of the surface on which the cell masses have been disseminated.

IPC Classes  ?

• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells